NDC 61755-019

Inmazeb

Atoltivimab, Maftivimab, And Odesivimab-ebgn

Inmazeb is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Regeneron Pharmaceuticals, Inc.. The primary component is Atoltivimab; Maftivimab; Odesivimab.

Product ID61755-019_1fc04220-a793-4dd3-812e-26389d422d3b
NDC61755-019
Product TypeHuman Prescription Drug
Proprietary NameInmazeb
Generic NameAtoltivimab, Maftivimab, And Odesivimab-ebgn
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2021-07-29
Marketing CategoryBLA /
Application NumberBLA761169
Labeler NameRegeneron Pharmaceuticals, Inc.
Substance NameATOLTIVIMAB; MAFTIVIMAB; ODESIVIMAB
Active Ingredient Strength483 mg/14.5mL; mg/14.5mL; mg/14.5mL
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 61755-019-01

1 VIAL, SINGLE-DOSE in 1 CARTON (61755-019-01) > 14.5 mL in 1 VIAL, SINGLE-DOSE (61755-019-00)
Marketing Start Date2021-07-29
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Inmazeb" or generic name "Atoltivimab, Maftivimab, And Odesivimab-ebgn"

NDCBrand NameGeneric Name
61755-018Inmazebatoltivimab, maftivimab, and odesivimab-ebgn
61755-019Inmazebatoltivimab, maftivimab, and odesivimab-ebgn

Trademark Results [Inmazeb]

Mark Image

Registration | Serial
Company
Trademark
Application Date
INMAZEB
INMAZEB
88716282 not registered Live/Pending
Regeneron Pharmaceuticals, Inc.
2019-12-05
INMAZEB
INMAZEB
88716277 not registered Live/Pending
Regeneron Pharmaceuticals, Inc.
2019-12-05

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.